The Pill That Targets Two Appetite Hormones at Once: What Amycretin's New Data Show

Every few months, it seems, a new molecule promises to change the weight-loss conversation. This time it is amycretin, an oral, once-daily tablet from Novo Nordisk that recently moved into large, pivotal Phase 3 trials after its Phase 2 data were published, with results that placed it among the most effective weight-loss medications tested to date — and, notably, in pill form.

What makes amycretin different

Most of the medications my patients ask me about — semaglutide, tirzepatide, retatrutide — work by mimicking gut hormones such as GLP-1 (glucagon-like peptide-1) and, in tirzepatide's case, GIP as well. Amycretin takes a different combination: it engages both the GLP-1 receptor and the amylin receptor in a single molecule. Amylin is a hormone made by the pancreas alongside insulin, and it works through separate pathways in the brainstem and hypothalamus to increase fullness and slow gastric emptying. Combining GLP-1 and amylin signaling in one drug is a strategy several companies are now racing to develop, because the two hormones appear to reduce appetite through complementary rather than overlapping brain circuits — in theory producing a stronger effect together than either alone.

What the data showed

In the reported trial, participants with obesity or excess weight taking the highest tested doses of oral amycretin lost weight in the range of roughly 20 to 25 percent of body weight over the treatment period, compared to low single-digit losses with placebo. Lower doses produced more modest, though still clinically meaningful, reductions of around 10 to 15 percent. These numbers put amycretin's oral formulation in the same range as injectable tirzepatide (which produces average losses of roughly 20 to 26 percent in its own trials) — a notable achievement, since oral peptide-based drugs have historically underperformed their injectable counterparts because stomach acid destroys most peptides before they can be absorbed. Novo Nordisk has used an absorption-enhancing formulation, similar in principle to the one used in oral semaglutide (Rybelsus), to get around this problem.

Side effects followed the pattern familiar from other GLP-1 and amylin-based drugs: nausea, vomiting, diarrhea, and reduced appetite, generally mild to moderate and improving over time, particularly when the dose was increased gradually. This gradual "dose titration" approach is standard practice with all drugs in this class and is one of the main reasons we start patients on low doses in clinic rather than jumping straight to a target dose.

Why this matters, and why caution is still warranted

I want to be direct with my patients about what these numbers do and do not mean. Phase 2 data are early: they typically involve a few hundred patients followed for a matter of months, not the thousands followed for a year or more that regulators require before approval. Durability, long-term cardiovascular and safety data, and real-world tolerability in patients with multiple comorbidities all remain to be established in the Phase 3 program that is now underway. History in this field also counsels humility — several previous "next-generation" candidates looked excellent in Phase 2 and produced more modest results, or ran into tolerability issues, once tested in larger and more diverse Phase 3 populations.

That said, the broader trend is unmistakable and clinically important. We are moving toward a future with more oral options for a condition that, until 2026, was almost exclusively managed with injections once diet, exercise, and behavioral therapy had been optimized. An effective oral tablet lowers a real barrier for patients who dislike injections, and it may also simplify manufacturing and, eventually, cost and access — issues that currently limit who can benefit from these medications in the Gulf and worldwide.

What I tell my patients

If you are currently doing well on an existing GLP-1 or dual-agonist medication, there is no reason to wait for the "next big thing" — amycretin is not yet approved and will not be available for at least a couple of years, pending Phase 3 results and regulatory review. If you have struggled specifically with injection-related barriers, this and other oral candidates are worth discussing with your physician as they become available. And as always, medication — oral or injectable — works best as part of a comprehensive plan that includes nutrition support, resistance exercise to preserve muscle, and, where appropriate, consideration of metabolic and bariatric surgery for patients with more severe obesity or obesity-related disease.

Sources: Novo Nordisk Phase 2 trial results in obesity/excess weight, published in The Lancet (2026); company Phase 3 program announcements (2026).